Means for treating prostate hypertrophy and prostate cancer

US6054432A · kind A · utility

Assignee

• Asta Medica Aktiengesellschaft · DE

Inventors

• Jurgen Engel · Alzenau, DE
• Thomas Reissmann · Frankfurt, DE
• Hilde Riethmuller-Winzen · Frankfurt, DE
• Jürgen Rawert · Cologne, DE

Key dates

• Filing date: Aug 7, 1997
• Grant date: Apr 25, 2000
• Expiry date: Aug 7, 2017

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P35/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A regime for therapeutic management of a benign prostatic hyperplasia and prostatic cancer employs Cetrorelix alone or in combination with .alpha.-reductase inhibitors or .alpha.-receptor blocking agents. The regimen reduces the volume of the prostate and avoids the side effects associated with testosterone levels being in a castration range Cetrorelix is administered at dosages between 0,5 mg/day and 20 mg/week or about 0.014 mg/kg body weight per day to 0,30 mg/kg body weight per week or at levels of about 25 to 120 mg of Cetrorelix per month or 0.376 mg kg to 1.71 mg/kg per month Cetrorelix can be administered with .alpha.-reductase inhibitors or .alpha.-receptor blocking agents.